Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clots in patients with atrial fibrillation, mechanical heart valves and venous thromboembolism but their therapeutic effect is always counterbalanced...
Read the latest publication digest "A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?".
This paper reviews current evidence for the reversal of the non-vitamin K oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban and edoxaban.
Target-specific oral anticoagulants (TSOACs) dabigatran, rivaroxaban and apixaban are approved for the prevention and treatment of thromboembolism in several clinical settings.
Read the latest publication digest "Anticoagulation reversal for intracranial haemorrhage in the era of the direct oral anticoagulants".
Read the latest publication digest "Managing bleeds related to oral factor Xa inhibitors with andexanet alfa or replacement agents".
The aim of this review is to summarize recent study data and recommendations on nonspecific and specific DOAC reversal strategies and to present the current evidence.
Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding...
Direct oral anticoagulants are associated with lower rates of bleeding than vitamin K antagonists, but life-threatening bleeding still occurs. Andexanet alfa is a catalytically inactive recombinant modified human factor Xa molecule that...
This paper reviews the current treatment options and the unmet needs in anticoagulation reversal.